Predicted Trait | |
Reported Trait | Ovarian cancer |
Mapped Trait(s) | ovarian carcinoma (EFO_0001075) |
Score Construction | |
PGS Name | OCPRS_Overall |
Development Method | |
Name | Known susceptibility loci (genome-wide significant SNPs) |
Parameters | Most strongly associated variant from each asociated region (p<5x10-8) |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 17 |
Effect Weight Type | NR |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000033 |
Citation (link to publication) | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 13,491 individuals (100%) |
PGS Evaluation | European: 100% 2 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST002748 Europe PMC: 25581431 |
13,491 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000112 | PSS000072| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Ovarian cancer in BRCA1 mutation carriers | HR: 1.28 [1.22, 1.34] | C-index: 0.579 [0.559, 0.6] | — | Country, birth year | — |
PPM000113 | PSS000073| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Ovarian cancer in BRCA2 mutation carriers | HR: 1.49 [1.34, 1.65] | C-index: 0.628 [0.592, 0.665] | — | Country, birth year | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000072 | BRCA1 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 50 |
PSS000073 | BRCA2 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis | — | [ ,
0.0 % Male samples |
— | European | Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry | CIMBA | Median censoring age (cases) = 57 |